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Abstract
Background Several rheological disorders of the erythro-
cytes, such as increased aggregation and decreased deform-
ability, have been observed in diabetes mellitus and have been
implicated in the development of diabetic microangiopathy.
Structural alterations of the erythrocyte membrane proteins
caused by the diabetic process may be at the origin of those
observations. In the present study, we searched for erythrocyte
membrane protein alterations in diabetic retinopathy.
Methods We examined peripheral blood samples from 40
type-2 diabetic patients with diabetic retinopathy of
variable severity (19 males and 21 females, mean age
66.8 years, Group A) and we compared them with samples
from 19 type-2 diabetic patients without diabetic retinop-
athy (13 males and six females, mean age 66.5 years,
Group B) and 16 healthy volunteers (eight males and eight
females, mean age 65.6 years, Group C). Erythrocyte
membrane ghosts from all samples were subjected to
SDS-PAGE, and the electrophoretic pattern of transmem-
brane and cytoskeletal proteins was analysed for each
sample. The protein quantification of each electrophoretic
band was accomplished through scanning densitometry.
Results No significant deviations from normal electrophore-
sis were observed in Groups B and C, apart from an increase
in band 8 in two samples from Group B (11%). In contrast, in
14 samples from Group A (35%) we detected increases in
protein band 8 and/or membrane-bound haemoglobin along
with a decrease in spectrin. Moreover, increased mobility of
band 3, an aberrant high molecular weight (MW) (>255 kDa)
band and a low MW (42 kDa) band were evident in ten
samples from Group A (25%). Glycophorins were altered in
46% of Group-A patients versus 38% of Group-B patients.
Females and patients with long duration of diabetes presented
more electrophoretic abnormalities.
Conclusions Structural alterations of the erythrocyte mem-
brane proteins are shown for the first time in association with
diabetic retinopathy. Their detection may serve as a blood
marker for the development of diabetic microangiopathy.
Further studies are needed to assess whether pharmaceutical
intervention to the rheology of erythrocytes can prevent or
alleviate microvascular diabetic complications.
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Introduction
Diabetic retinopathy constitutes a major social problem, as
it is present in nearly 100% of patients who have had type 1
diabetes mellitus for 20 years and in nearly 80% of those
with type 2 diabetes of this duration [14]. Furthermore,
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diabetic retinopathy is the leading cause of blindness in
working-age individuals in the industrialised world [33]. Non-
proliferative diabetic retinopathy begins with basement
membrane thickening and loss of capillary pericytes and
endothelial cells [23], progressively leading to microaneur-
ysms, retinal haemorrhages, venous beading, leakage, and
macular oedema. In later stages, capillary closure causes
retinal ischemia, which is followed by retinal neovasculari-
zation, the hallmark of proliferative diabetic retinopathy, thus
increasing the probability of severe visual impairment.
Multiple pathophysiological disorders have been impli-
cated in the development of diabetic microangiopathy,
including increased plasma and whole blood viscosity
[19] as well as rheological disorders of the erythrocytes,
namely increased erythrocyte microviscosity, aggregation,
and adhesiveness, and decreased erythrocyte deformability
[38]. Rheological disorders of the erythrocytes may be
related to specific changes of the mechanical properties of
the erythrocyte membrane, potentially associated with
structural alterations of membrane lipids or proteins occur-
ring in diabetes of long duration.
The isolation of erythrocyte membrane ‘ghosts’ free of
haemoglobin and cytoplasm [10] enabled the study of the
erythrocyte membrane in detail. The erythrocyte membrane
is composed of a lipid bilayer, penetrated by the trans-
membrane proteins, and of the membrane skeleton, formed
by the peripheral or cytoskeletal proteins. The membrane
skeleton is a bidimensional network that laminates and
supports the inner surface of the bilayer. Skeleton proteins
are connected to transmembrane ones through anchoring
proteins, particularly ankyrin and protein 4.1. The trans-
membrane proteins include mainly the anion transport
protein band 3 and the glycophorins, while the cytoskeletal
proteins comprise mainly spectrin and actin [8].
A number of hereditary haemolytic anaemias, often
associated with erythrocyte shape and deformability abnor-
malities, derive from mutations affecting genes that encode
erythrocyte transmembrane, cytoskeletal, or anchoring
proteins [8]. If rheological disorders of the erythrocytes
indeed participate in the pathogenesis of diabetic micro-
angiopathy, this may well reflect corresponding erythrocyte
membrane protein abnormalities. Thus, in the present study
we searched for possible structural alterations of the
erythrocyte membrane proteins in diabetic retinopathy, as
well as for a potential link of such alterations to the severity
of retinopathy.
Materials and methods
Three groups of subjects were studied: (1) type-2 diabetic
patients with diabetic retinopathy of variable severity
(Group A, n=40); (2) type-2 diabetic patients without
diabetic retinopathy (Group B, n=19); and (3) healthy non-
diabetic age-matched volunteers, who served as controls
(Group C, n=16). The main demographic characteristics of
those three groups are presented in Table 1. The study
gained approval from the local ethics committee at the
University Hospital of Patras, Greece, and informed
consent was obtained from all subjects. The investigations
were carried out in accordance with the principles of the
Declaration of Helsinki. All subjects were offered a
thorough eye examination, including visual acuity mea-
surement, slit-lamp examination, tonometry, dilated oph-
Table 1 Demographic, clinical, and laboratory characteristics of patients (values are expressed as the mean±SD)
Subject characteristic Group A Group B Group C
Diabetic retinopathy Diabetes without retinopathy Control
Number (n) 40 19 16
Gender (male/female) 19/21 13/6b 8/8
Age (years) (range) 52–83 34–84 33–90
Age (years) (mean±SD) 66.8±6.6 66.5±12.9 65.6±14.9
Duration of diabetes (years) 16.4±8.8a 9.8±8.2 –
Non-insulin/insulin treated 17/23b 16/3 –
HbA1c (%) 8.7±1.6 8.9±1.6 5.8±0.6
a
Glucose (mM) 12.2±4.5 10.9±3.8 5.3±0.8a
Cholesterol (mg/dl) 224.7±47.0 232.5±39.2 241.9±44.0
Triglycerides (mg/dl) 236.8±168.1 198.9±74.2 151.8±64.7
Erythrocyte count (106/μl) 4.61±0.67 5.05±0.76 4.73±0.61
Haematocrit (%) 38.1±4.5a 41.2±3.8 41.5±3.9
Haemoglobin (mg/dl) 12.9±1.7a 14.0±1.5 14.1±1.7
a Statistically significant difference versus the other two groups (unpaired Student’s t-test, P<0.05)
b Statistically significant difference versus the other two groups (chi-square test, P<0.05)
All other differences were not statistically significant
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thalmoscopy with stereoscopic colour photos, and fluores-
cein angiography. The degree of diabetic retinopathy was
defined according to the Early Treatment Diabetic Retinop-
athy Study (ETDRS) guidelines [9, 12] in the most severely
affected eye (Table 2).
After overnight fasting, peripheral venous blood was
collected from all subjects into acid citrate EDTA tubes.
Serum glucose, cholesterol, and triglycerides, as well as
erythrocyte count, haematocrit, haemoglobin, and HbA1c
were measured. The erythrocytes were separated from
plasma by centrifugation at 3,000 rpm for 10 min.
Membrane ghosts were prepared by hypotonic lysis of
erythrocytes in phosphate buffer at 4°C as described by
Dodge et al. [10], with the addition of 0.3 mmol/l phenyl-
methyl-sulfonyl-fluoride to the lysis buffer to inhibit
protease activity. Total protein concentration of each sample
was determined using the Bradford protein assay reagent,
with bovine serum albumin (Bio-Rad Laboratories, UK)
serving as standard. The protein components of each
sample were determined by one-dimensional sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing conditions using the discontinuous
buffer system of Laemmli [27] and homogeneous or 5–15%
linear acrylamide gradient. The gels were stained either
with Coomassie blue R-250 for protein staining, or with
Periodic Acid-Schiff (PAS) reagent for carbohydrate stain-
ing and visualization of glycophorins, as described by
Fairbanks et al. [13].
Individual membrane proteins were identified and
quantified, as required, by lengthwise scanning densitom-
etry of either Coomassie blue- or PAS-stained SDS-PAGE
gels, using the Gel Analyzer v. 1.0 image-processing
program (Biosure, Athens, Greece). The molecular weight
(MW) definition of aberrant bands was compared with a
lane of MW protein standards. Each sample was analysed
in triplicate gels alongside with numerous reference
samples (from healthy subjects or patients’ control group).
The relative amount of each major protein band was
expressed as a percentage of total bands measured (namely,
spectrin, band 3, 4.1, 4.2, 5, 6, 7, 8, and globin) upon the
densitometric scanning of each track. The mean values
presented by the studied patient groups (A and B) were
compared between them and with those presented by the
healthy controls (Group C). Regarding the quantification of
the glycophorins, the results were reported as the ratio of
each PAS-stained band to the sum of the main bands
revealed in each track after double staining of the gel with
PAS reagent and (subsequently) Coomassie blue. Protein
deficiency/excess was considered significant whenever the
mean density of that protein was lower/higher than the
mean density minus/plus 2× standard deviation (SD)
presented by the reference samples for the same protein.
Hence, any value being out of the described range (i.e.
mean density in samples from normal reference people ±2
SDs) was defined as pathological.
Each value was expressed as the mean±SD. The
unpaired Student’s t-test and the chi-square test were used
to compare mean values and frequencies between groups,
respectively. In each case, a level of P<0.05 was
considered statistically significant.
Results
The main clinical characteristics of the studied groups are
presented in Table 1. Mean age was similar among the
groups, whereas the duration of diabetes was significantly
longer in Group A (diabetic retinopathy) than in Group B
(diabetes without diabetic retinopathy). Also, as expected,
the proportion of insulin-treated patients was significantly
higher in Group A compared with Group B.
According to the ETDRS classification (Table 2), 18
patients (45%) of Group A were diagnosed with non-
proliferative diabetic retinopathy, whereas 22 patients
(55%) had already developed proliferative diabetic retinop-
athy (Table 3). Sixteen patients (40%) of Group A
presented high-risk proliferative diabetic retinopathy
(Fig. 1).
Table 2 Severity levels of diabetic retinopathy (based on the
Abbreviated Summary of the ETDRS Final Scale of Diabetic
Retinopathy Severity for Individual Eyes [7]). NPDR non-proliferative
diabetic retinopathy, PDR proliferative diabetic retinopathy, IRMA
intraretinal microvascular abnormalities, NVE new vessels elsewhere,
NVD new vessels on or within one disc diameter of optic disc
Severity level
of DR
Definition
No retinopathy Absence of diabetic lesions
Mild NPDR Microaneurysms only, or microaneurysms plus
hard exudates, soft exudates (cotton-wool spots)
and/or mild retinal hemorrhages
Moderate NPDR Microaneurysms plus mild or moderate IRMA,
moderate or severe retinal hemorrhages, or
venous beading in one quadrant only
Severe NPDR Severe retinal hemorrhages in four quadrants, or
venous beading in at least two quadrants, or
severe IRMA in at least one quadrant
Mild PDR NVE less than half of disc area in one or more
quadrants
Moderate PDR NVE greater or equal to half of disc area in one or
more quadrants, or NVD less than a quarter to a
third of disc area
High-risk PDR NVD greater or equal to a quarter to a third of
disc area and/or vitreous hemorrhage
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The results of laboratory parameters are also shown in
Table 1. Serum glucose and HbA1c were significantly
higher in Groups A and B compared with controls.
Moreover, Group A presented significantly lower haema-
tocrit and haemoglobin compared with the other groups.
Concerning the SDS-PAGE results, there were no
significant deviations from normal Coomassie-blue stained
electrophoresis of total membrane proteins observed in
Groups B (diabetes without diabetic retinopathy) and C
(healthy controls), apart from an increase in protein band
8 shown in two samples (11%) from Group B, 120% and
150% above normal values, respectively. In contrast, in 14
samples (35%) from Group A (diabetic retinopathy) we
detected deviations concerning increases in protein band
8 (100% to 200% above normal values) and/or membrane-
bound haemoglobin (100% to 340% above normal values)
along with a decrease in the major skeletal protein spectrin
(20% below normal values). The increase in protein band
Table 3 Distribution of abnormal SDS-PAGE samples upon the
degrees of diabetic retinopathy
Severity level of DR
in worse eye
Number of
patients
Number of patients with
abnormal electrophoresis
Mild NPDR 2 0 (0%)
Moderate NPDR 9 5 (56%)
Severe NPDR 7 5 (71%)
Mild PDR 2 1 (50%)
Moderate PDR 4 3 (75%)
High-risk PDR 16 10 (63%)
Total 40 24 (60%)
Fig. 1 Red-free photograph and late-phase fluorescein angiography of
the right eye in a 52-year-old male patient with high-risk proliferative
diabetic retinopathy according to the ETDRS classification guidelines,
as new vessels cover one half of the disc area. Areas of capillary non-
perfusion can also be observed in the retinal periphery. Duration of
diabetes was 10 years. The patient was under insulin treatment. This
patient had abnormal electrophoresis with increased mobility of
protein band 3
Fig. 2 SDS-PAGE (Laemmli 5–15% linear gradient) of 15 μg ghosts
after staining with Coomassie blue. The arrows show the increase of
protein band 8 (21 kDa) and membrane-bound haemoglobin (16 kDa)
in a representative sample from a patient with diabetic retinopathy (A)
in comparison with a control sample (C). The right column shows
MW in kDa
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8 was the most common encountered deviation (70% of the
disturbed ghosts), followed by those of membrane-bound
haemoglobin and spectrin (40% and 20% of the disturbed
ghosts, respectively). In some cases the ghosts were
characterized by combined deviations concerning band
8 and haemoglobin (Fig. 2), or band 8, haemoglobin and
spectrin.
Furthermore, increased electrophoretic mobility of pro-
tein band 3 (Fig. 3), as well as an aberrant high MW (above
255 kDa) electrophoretic band and a low MW band of
42 kDa (Fig. 4) were evident in ten samples (25%) from
patients with diabetic retinopathy (Group A).
The distribution of those Coomassie-blue stained electro-
phoretic abnormalities upon the degrees of diabetic retinop-
athy is given in Table 3. While ten patients with high-risk
proliferative diabetic retinopathy (63%) had abnormal
electrophoresis (Fig. 1), no direct correlation of the latter
with the severity of retinopathy was evident (Table 3).
Subsequent staining of the SDS-PAGE gels with the PAS
reagent for the detection of membrane glycophorins
revealed a deficiency in one or more sialic acid-positive
bands in 46% versus 38% of the patients of Groups A and
B, respectively. This difference was statistically significant
(chi-square test, P<0.001). Notably, in Group-B membrane
Fig. 3 SDS-PAGE (Laemmli 5–15% linear gradient) of 15 μg ghosts
after staining with Coomassie blue. The arrow shows the increased
electrophoretic mobility of protein band 3 in a representative sample
from a patient with diabetic retinopathy (A) in comparison with a
control sample (C). The right column shows MW in kDa
Fig. 4 SDS-PAGE (Laemmli 5–15% linear gradient) of 15 μg ghosts
after staining with Coomassie blue. The arrow shows the aberrant
high MW (above 255 kDa) electrophoretic band in a representative
sample from a patient with diabetic retinopathy (A) in comparison
with a control sample (C). The right column shows MW in kDa.
HMWB high molecular weight band
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ghosts the deficiencies predominantly concerned glyco-
phorins B2, A, or C (83% of the aberrations), whereas in
Group A the deficiencies predominantly concerned the
band of glycophorin A dimers (55% of the aberrations).
Furthermore, Group-A membrane ghosts were commonly
characterized by generalized reductions in almost all
glycophorin bands (20% of the samples). In 12% of both
groups, a band with MW close to that of glycophorin A
dimers was observed (Fig. 5, upper image), whereas in
some patients with diabetic retinopathy (Group A) more
than one aberrant sialoglycoprotein bands appeared with
MW of 70 and 55 kDa (Fig. 5, lower image), probably
having arisen from the original glycophorin A and B homo-
and hetero-dimer bands, respectively.
Females and patients with long duration of diabetes
presented more frequent electrophoretic abnormalities.
Abnormal electrophoresis was observed in 14/21 females
(67%) versus 10/19 males (53%) of Group A (chi-square
test, P<0.001). Moreover, duration of diabetes was 21.4±
8.5 years in patients of Group A with abnormal electropho-
resis, whereas it was 14.9±8.4 years in patients of Group A
with normal electrophoresis (unpaired Student’s t-test,
P<0.001). On the other hand, no correlation of abnormal
electrophoresis was observed with any of the following
parameters: age, insulin treatment, HbA1c, glucose,
cholesterol, triglycerides, erythrocyte count, haematocrit,
and haemoglobin.
Discussion
In the present study we demonstrate for the first time the
existence of structural alterations of the erythrocyte mem-
brane proteins in diabetic patients that have already
developed diabetic retinopathy. Abnormal Coomassie-blue
stained electrophoresis of erythrocyte ghost membranes
was revealed in more than half of the examined patients
with diabetic retinopathy, in all severity grades except mild
non-proliferative diabetic retinopathy. In contrast, only 11%
of diabetic patients without retinopathy and, as expected, no
healthy control subject manifested Coomassie-blue stained
electrophoretic abnormalities. In addition, glycophorins
were altered in 46% of Group-A patients versus 38% of
Group-B patients. Furthermore, long duration of diabetes,
which is a more common characteristic in vascular
complications of diabetes, seemed to correlate also with
abnormal electrophoretic patterns of the erythrocyte mem-
brane proteins.
Fig. 5 SDS-PAGE (Laemmli 12% linear gradient) of 80 μg ghosts
after staining with PAS reagent for the detection of glycophorins. The
right column shows MW in kDa. Upper image: The arrowheads show
a band with MW close to that of glycophorin A dimers (approximately
80 kDa) in representative samples from a patient with diabetic
retinopathy (A) and a patient with diabetes mellitus without diabetic
retinopathy (B). Two normal control samples (C1 and C2) are also
shown for comparison. Lower image: The arrowheads show two
aberrant sialoglycoprotein bands with MWs of approximately 70 and
55 kDa in a representative sample from a patient with diabetic
retinopathy (A). Two normal samples are also shown for comparison,
belonging to a patient with diabetes mellitus but no diabetic
retinopathy (B) and to a patient of the control group (C), respectively
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Hyperglycaemia resulting from uncontrolled glucose
regulation is widely recognised as a causal link between
diabetes and diabetic complications [37]. Chronic hyper-
glycaemia causes oxidation and non-enzymatic glycosyla-
tion (Maillard reaction) of proteins and this applies on the
erythrocyte membrane proteins too [31, 45]. Slow turnover
of the erythrocyte membrane proteins makes them partic-
ularly susceptible to hyperglycaemia [31]. Erythrocyte
membrane glycosylation reduces the negative surface
electric charge [4, 34] due to cleavage of terminal sialic
acid components of glycophorin A, leading to accelerated
aging of erythrocytes [28]. It also increases erythrocyte
aggregation [36] and accumulates advanced glycation end-
products (AGEs), which have been associated with eryth-
rocyte deformability defects [6] and with microvascular
complications of diabetes [7]. Crossline, a special AGE in
the erythrocyte membrane is elevated in diabetic retinopa-
thy [47]. In the present study, we were able to show some
of the erythrocyte membrane protein alterations that may
ensue from altered glucose metabolism to produce diabetic
retinopathy.
Erythrocyte membrane proteins serve specific functions.
Band 3, for instance, which is the most abundant
erythrocyte transmembrane protein and which presented
altered mobility in ten samples of Group A in our study, is
responsible for anion exchange at the level of plasma
membrane [24]. Other transmembrane proteins serve as
pumps or channels for the movement of ions and the
transport of glucose and other small molecules. In addition,
cytoskeletal proteins are important for the maintenance of
the biconcave shape and structural integrity of the erythro-
cyte. Thus, disorders of the erythrocyte membrane proteins
may alter the surface electric charge and the mechanical
properties of plasma membrane, namely shape and deform-
ability, the latter reflecting the elastic reserve of the
erythrocyte when it receives shear stress forces at its
passage through small vessels or capillaries. In other words,
erythrocyte membrane protein alterations are linked to
altered erythrocyte rheology.
There is growing evidence in the literature in favour of
the association of haemorrheological abnormalities with
diabetes mellitus [5, 11, 19, 30, 38, 48]. Those abnormal-
ities are more and more thought to participate in the
pathogenesis of diabetic microangiopathy. In that context,
altered rheology of erythrocytes can lead to increased
aggregation, endothelial damage, and capillary closure.
This particularly applies on diabetic retinopathy, the most
common of diabetic vascular microangiopathies [23].
Characteristically, Vekasi et al. [43] found pathological
plasma and whole blood viscosity with concomitant
increased red blood cell aggregation in patients with
diabetic retinopathy compared with controls. Moreover,
Goldstein et al. [17] have recently reported differences in
the mechanical properties of red blood cells between non-
proliferative and proliferative diabetic retinopathy. Our
results support those findings by casting light on the
pathogenic mechanisms linking erythrocyte membrane
protein alterations to subsequent altered erythrocyte rheol-
ogy and to the development of diabetic retinopathy.
There have been several reports in the literature
describing a variety of erythrocyte membrane protein
alterations in diabetic humans or animals. Schwartz et al.
[38] demonstrated oxidation of spectrin in diabetic eryth-
rocytes. Adewoye et al. [1] reported absent spectrin in
insulin-dependent diabetes mellitus, and increased ankyrin
and band 6 in both insulin- and non-insulin-dependent
diabetes mellitus. Also, Kaymaz et al. [25] showed weaker
actin (band 5), absent band 4.5 (related to glycophorins),
and absent band 4.9 (dematin) in diabetic cats. However, in
those studies most often no data is given about the presence
of diabetic microangiopathy. In the present study, we
showed that electrophoretic alterations of the erythrocyte
membrane proteins were most frequently manifested in the
presence of diabetic retinopathy. We therefore believe that
the detection of such alterations may help to clarify the
pathogenic steps that contribute to the development of
diabetic retinopathy, but it may also serve as a blood marker
for the existence of diabetic microangiopathy or as a sign of
increased risk to develop diabetic microangiopathy.
In agreement to the latter, red blood cell ultrastructure
alterations have recently been proposed as a possible
progression marker in non-insulin-dependent diabetes mel-
litus [42]. Interestingly, not only the erythrocytes but also
the leukocytes seem to play a role in the pathogenesis and/
or progression of diabetic retinopathy. More specifically,
integrins are believed to increase leukocyte adhesion to the
retinal endothelium. Elevated levels of integrin CD18 (a
transmembrane receptor) on the neutrophils were indicated
in a late report as a potential severity marker of diabetic
retinopathy in type 2 diabetic patients [41]. Nevertheless,
only clinical practice will show whether the above possible
severity markers of diabetic retinopathy will assume any
utility in the future.
Several possible interpretations to those alterations can
be drawn from the literature. Accelerated aging of eryth-
rocytes in diabetes is one of them [28], consisting of the
labelling of erythrocytes with the senescent cell antigen,
where an IgG antibody adheres and induces erythrocyte
disruption by macrophages [24]. The reported relation of
AGEs with macrophages [44], with chemotactic behaviour
to human blood monocytes [26], and with increased
macrophage colony stimulating factor [46] in diabetic
microangiopathy supports this mechanism. Interestingly, it
has been reported that different chemical insults within the
erythrocyte can result in a common ‘message’ on the
outside of the cell, such that the cell appears ‘prematurely’
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aged [21]. Other possible mechanisms include increased
susceptibility of the erythrocyte membrane proteins to lysis
by endogenous enzymes reported in diabetes [16, 22], as
well as an up-regulation of glucose transporters in the
erythrocytes of subjects with chronic hyperglycaemia
described by Harik et al. [18]. Increased protein lysis by
endogenous enzymes in diabetes is more frequent in
females [16], and this gender predilection was expressed
in altered electrophoresis in our results. The above
mechanisms may account for altered bands or the emer-
gence of new bands in erythrocyte membrane electropho-
resis seen in the present study.
Protein band 8 was increased in 11% of diabetic patients
without diabetic retinopathy and in 35% of patients with
diabetic retinopathy, while it was the most common
encountered electrophoretic deviation in affected ghosts.
Band 8 has not been characterized, but it has been shown in
combination with increased proportion of membrane-bound
haemoglobin in erythrocytes from anaemic patients [3].
Increased amounts of band 8 have also been reported by
other groups in the membranes of metabolically stressed red
blood cells [32].
Increased membrane-bound haemoglobin was found
only in diabetic retinopathy samples in our study. Previous
studies have shown increased proportion of membrane-
bound haemoglobin in a variety of stressed erythrocytes,
like in in vivo [35] or in vitro senescent normal eryth-
rocytes, in erythrocytes with defective haemoglobin [2, 3],
and in erythrocytes oxidatively stressed in vitro by various
haemolytic agents [29]. In addition, thalassaemic mem-
branes are generally characterized by an increased binding
of cytoplasmic proteins like haemoglobin and catalase [2].
The concomitant decrease in spectrin observed in
diabetic retinopathy samples is probably indicative of
increased susceptibility of membrane proteins to endog-
enous proteolysis, previously shown in diabetes mellitus
[16, 22].
Furthermore, increased mobility of band 3 and aberrant
electrophoretic bands with MWs of 42 kDa and above
255 kDa were found only in diabetic retinopathy samples in
the present study. A similar shift in the apparent molecular
mass of band 3 glycoprotein has been detected in all type II
congenital dyserythropoietic anaemias (CDA II, HEMPAS)
due to underglycosylation of the protein [15]. However, at
present we are not able to know whether the increased
electrophoretic mobility of band 3 in patients with diabetic
retinopathy is attributed to a glycosylation defect or to
increased proteolysis.
As for the aberrant low MW bands, they probably arise
from increased proteolysis of original membrane proteins.
The high MW band of above 255 kDa has previously been
found in membranes of oxidatively stressed erythrocytes as
a crosslinkage event between spectrin and haemoglobin.
The formation of spectrin-haemoglobin crosslinking repre-
sents a well-known oxidant damage of the senescent
erythrocyte membrane [40]. Its reproduction in vitro by
hydrogen peroxide treatment is associated with echinocyte
transformation, membrane rigidity, adherence and phago-
cytosis [39].
Finally, regarding PAS staining results of the present
study, a deficiency in PAS-positive bands was significantly
more frequent in diabetic retinopathy (Group A) samples
(46%) compared with that of Group B samples (38%). This
may constitute evidence of more advanced glycosylation of
the erythrocyte membrane proteins in diabetic retinopathy.
Of interest, there was a different specificity regarding the
sialoglycoproteins affected in Group A and B samples, with
the deficiency of glycophorin A dimers and total glyco-
phorin bands being dominant in Group A samples. Future
research may reveal the biochemical basis of this distinction
and, possibly, its clinical importance.
From a clinical point of view, the results of our study
raise also the issue of a possible preventive or therapeutic
intervention to erythrocyte rheology in diabetic retinopathy.
The reported increased erythrocyte deformability in type 2
diabetic patients with retinopathy by Ginkgo biloba extract
761 [20] is an example of that trend, yet more literature data
are required. As AGEs are irreversibly attached to macro-
molecules and their levels do not decline when glucose
levels are corrected, inhibition of AGE formation could be
combined with agents that enhance erythrocyte flexibility
and improve blood rheology. Prevention of diabetic
retinopathy could therefore be directed onto the inhibition
of erythrocyte membrane protein glycosylation, the en-
hancement of erythrocyte deformability, and the reduction
of erythrocyte aggregation.
In conclusion, structural alterations of the erythrocyte
membrane proteins, which probably derive from oxida-
tion and nonenzymatic glycosylation of those proteins in
chronic diabetes and which can affect the erythrocyte
rheology, may be associated with the development of
microvascular complications of diabetes, in particular
diabetic retinopathy. A lot of such protein alterations
are shown exclusively in association with diabetic
retinopathy in the present study. Their detection may
serve as a blood marker for the development of diabetic
microangiopathy or as a sign of increased risk to develop
diabetic microangiopathy. Further studies are needed to
assess whether pharmaceutical intervention to the rheol-
ogy of erythrocytes can prevent or alleviate microvascu-
lar diabetic complications.
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